Guanfacine in Children with Tourette's Disorder

ID Number 12-1556

Principal Investigator(s)
Barbara Coffey

Department(s) or Division(s)


The purpose of this study is 1) to determine the best dose of extended release guanfacine that may be helpful in treating Tourette's Disorder (TD); 2) to better understand extended release guanfacine's adverse effects; and 3) to determine if further study of the medication is warranted. Guanfacine (extended release) is not approved by the Food and Drug Administration for treatment of TD, but it is approved for treatment of high blood pressure and ADHD. However, guanfacine, in a short-acting form, has been shown to be effective for treatment of tics in TD.

Currently closed to enrollment.

Contact Information
Laura Ibanez
(212) 659-1676

Recruiting Patients: No